# A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

> **NCT06008093** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 100 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06008093
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2026-12-08
- **Final completion:** 2027-12-23
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008093, "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06008093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*